77.47
-0.17 (-0.22%)
| Penutupan Terdahulu | 77.64 |
| Buka | 77.27 |
| Jumlah Dagangan | 269,881 |
| Purata Dagangan (3B) | 162,096 |
| Modal Pasaran | 758,211,392 |
| Harga / Buku (P/B) | 12.40 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 18 May 2026 |
| EPS Cair (TTM) | -0.400 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.30% |
| Nisbah Semasa (MRQ) | 88.27 |
| Aliran Tunai Operasi (OCF TTM) | -4.14 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.40 M |
| Pulangan Atas Aset (ROA TTM) | -10.57% |
| Pulangan Atas Ekuiti (ROE TTM) | -11.21% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Bright Minds Biosciences Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | -3.5 |
| Purata | -0.25 |
|
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 22.55% |
| % Dimiliki oleh Institusi | 74.12% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Seven Grand Managers, Llc | 31 Mar 2026 | 120,000 |
| Julat 52 Minggu | ||
| Median | 145.00 (87.17%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 04 Mar 2026 | 145.00 (87.17%) | Beli | 79.31 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |